|Company name||Surface Oncology, Inc.|
NEW YORK, August 26, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Surface Oncology, Inc. (NYSE: SURF) on behalf of Surface Oncology investors. Our investigation concerns whether Surface Oncology has violated the federal securities laws and/or engaged in other unlawful business practices.
Our investigation concerns potential violations of federal securities laws pursuant to the company’s April 2019 initial public offering (“IPO”). On April 19, 2018 Surface Oncology held its IPO, offering shares at $15.00. Since it’s IPO, Surface Oncology stock has plummeted, and currently trades at just $2.22, or less than 15% of it’s IPO price.
If you purchased or otherwise acquired Surface Oncology shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.